Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by Biotech777on Jan 13, 2014 1:25pm
172 Views
Post# 22085495

RE:RE:Interesting Article on New Heart Attack Predictor

RE:RE:Interesting Article on New Heart Attack Predictor
Inflammation causes the plaque rupture. Technically inflamation causes the thinnning of the firbrous cap that surrounds the atheroma which eventually can lead to plaque rupture. Keep in mind that inflammation is a very broad term. Inflammation within the arterial wall is simply referring to the over expression of certain proteins that are part of the cascade which can lead to the rupture of the thin fibrous cap. However, plaques rupture all the time and are rarely symptomatic. The process of rupture and healing is continuously happening within your aterial wall. This process is much more detailed than I am stating here, and its not as simple as sayng that RVX-208 is anti-inflammatory and therefore it will have a similar effect as something else that is anti-inflammatory. Of note also is that when measuring certain "inflammatory" markers, it is important to undertsand that there often is a difference within the arterial wall and versus circulating in plasma. This has a huge impact and effects the choice and method of what you choose to measure as part of a study. This is why there is so much confusion over this area from one study to the next.
Bullboard Posts